SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is generating massive social media buzz and extreme volatility driven by a major executive order aimed at fast-tracking psychedelic research for PTSD and addiction. Community discussion is dominated by speculation over a potential short squeeze due to the stock's low float, with many retail traders highlighting its ibogaine supply chain as a key catalyst while others debate the risks of a volatility-driven pump.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant market volatility after a Blue Origin launch resulted in the BlueBird 7 satellite being placed into an unsustainably low orbit, leading to its required de-orbiting. While the company maintains that insurance will mitigate financial losses and that its broader constellation deployment roadmap remains intact, the community is actively debating the reliability of launch providers, the impact on launch cadence, and whether this setback represents a temporary operational hurdle or a deeper execution risk.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

crow with knife is generating intense community interest due to its unique multichain presence and deflationary burn mechanism. Supporters are actively rallying behind the project's organic growth and cultural identity, frequently encouraging others to increase their positions in what they describe as a community-driven movement.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing an aggressive short squeeze and significant volume surge, fueled by Bitcoin's recovery and optimism surrounding institutional accumulation. The community is sharply divided, with bulls celebrating the potential for rapid gains as the stock decouples from recent weakness, while skeptics continue to debate the long-term sustainability of the company's leverage and dividend strategy.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is experiencing a significant surge after Greenland authorities approved the transfer of a majority interest in the Tanbreez project, solidifying the company's 92.5% ownership of one of the world's largest heavy rare earth deposits. The community is actively discussing the stock's potential for a massive short squeeze and long-term valuation expansion, with many investors anticipating further upward momentum as the news de-risks the project and enhances its strategic importance for Western supply chains.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing a surge in bullish momentum as investors anticipate a strong earnings report and the potential for S&P 500 inclusion later this year. The community is heavily divided, with long-term shareholders holding firm for a recovery to previous highs while active traders engage in intense battles with short sellers amid significant call-option volume and volatility.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp. is generating significant investor buzz following its recent NYSE IPO, with market participants closely monitoring the drone manufacturer due to its strong defense sector positioning and ongoing government contract activity. Community discussion is focused on the stock's high-volatility momentum, with traders actively comparing its growth potential to other defense technology players while debating the sustainability of its post-debut price action.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Core Scientific is trending as investors focus on its pivot from Bitcoin mining to AI data center infrastructure and high-density compute hosting. The community is actively discussing the company's long-term potential supported by major power capacity contracts, alongside institutional accumulation and heavy call option activity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to the company's global expansion efforts and potential regulatory catalysts, while the community remains fiercely divided over FDA relations and short-selling activity. Enthusiastic supporters are highlighting international clinical partnerships as a way to bypass domestic delays, while traders continue to closely watch for signs of a squeeze as discussions center on the company's long-term immunotherapy platform.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster Inc. is capturing significant investor attention as it evolves into a full-stack 'Physical AI' platform following its acquisition of Stereolabs, with sentiment shifting toward its long-term potential in industrial automation, robotics, and smart infrastructure. Community discussions are currently dominated by analysis of the company's path to profitability, the strategic advantages of its sensor-software integration, and the impact of domestic sourcing policies on future market dominance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lipocine (NASDAQ:LPCN) Director Buys $81,200.00 in Stock

Lipocine Inc. (NASDAQ:LPCN - Get Free Report) Director John Higuchi bought 40,000 shares of the firm's stock in a transaction dated Tuesday, April 7th. The stock was purchased at an average cost of...

Mahesh Patel Purchases 25,000 Shares of Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc. (NASDAQ:LPCN - Get Free Report) CEO Mahesh Patel purchased 25,000 shares of Lipocine stock in a transaction that occurred on Monday, April 6th. The shares were bought at an average cost...

What's Going On With Lipocine Stock On Monday?

Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouraging subgroup data.read more...

Insider Buying: Lipocine (NASDAQ:LPCN) CEO Purchases 25,000 Shares of Stock

Lipocine Inc. (NASDAQ:LPCN - Get Free Report) CEO Mahesh Patel purchased 25,000 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The shares were acquired at an average cost of $2.02 per share, with a total value of $50,500.00. Following the completion of the...

<ul class="summary-bullets"><li>While the trial failed its primary endpoint of significant reduction in depression severity, the drug was well tolerated and demonstrated a favorable safety profile, the company said.&nbsp;</li><li>Lipocine, however, said that it has identified signals in a post hoc analysis that could indicate a potential development path for LPCN 1154.</li><li>The company said it will preserve capital and engage with shareholders to evaluate all options available to the company going forward.</li></ul>Shares of Lipocine Inc. (LPCN) fell 78% on Thursday after the company said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.While the trial failed its primary endpoint of significant reduction in depression severity, the drug was well tolerated and demonstrated a favorable safety profile enough to support outpatient administration without the need for healthcare provider monitoring, the company said. No treatment-related severe or serious adverse events were reported and no cases of excessive sedation or loss of consciousness were observed, it added.<h2 class="st-heading-2">What’s Next For Lipocine?</h2>Lipocine, however, said that it has identified signals in a post hoc analysis that could indicate a potential development path for LPCN 1154. The company has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with postpartum depression based on the post hoc analysis results, the company said.While it waits for the FDA to get back, the company said it will preserve capital and engage with shareholders to evaluate all options available to the company going forward, including continued development of LPCN 1154, development of other product candidates, strategic transactions, partnerships, and other opportunities, it said.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around LPCN rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user drew focus to the company’s remaining pipeline, which includes experimental drugs for the treatment of non-alcoholic steatohepatitis, for the management of symptoms associated with cirrhosis and another for the prevention of recurrent preterm birth.<stembedurl>https://www.stocktwits.com/Boknow/message/649308142</stembedurl>Another user expressed hopes for a minor recovery after the crash. &nbsp;<stembedurl>https://www.stocktwits.com/Ruttobillions/message/649292640</stembedurl><a href="https://stocktwits.com/symbol/LPCN">LPCN stock</a> has dropped 37% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sgml-stock-soars-on-100-m-bank-guarantee-retail-says-one-last-hurdle-is-behind/cZ7xCWQRI8Z">SGML Stock Soars On $100M Bank Guarantee, Retail Says 'One Last Hurdle' Is Behind</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Lipocine is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

LPCN Stock Crashes 78%— Here’s Why 

Lipocine said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.

Equity

Lipocine said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.


Lipocine Stock Tanks 78% After Phase 3 Oral Brexanolone Trial Failed To Meet Primary Endpoint

(RTTNews) - Shares of Lipocine Inc. (LPCN) are falling about 78 percent on Thursday morning trading following the announcement of topline results from its Phase 3 placebo-controlled trial, which failed to meet the primary endpoint. The trial evaluated LPCN 1154 or oral brexanolon...

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with...

Lipocine (NASDAQ:LPCN) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Lipocine from a "sell" rating to a "hold" rating in a report on Sunday...

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 PR Newswire SALT LAKE CITY, March 10...

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?

Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

LPCN
Lipocine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LPCN News

LPCNLipocine Inc